AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21240818 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 19228175 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 4.5 mg/day
Number of subjects: 169
Study 19228175 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day
Number of subjects: 169
Study 19228175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 19228175 — intervention group
Group type: EXPERIMENTAL
Intervention: Both active drugs
Number of subjects: 169
Study 16966491 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe (10 mg/day)
Number of subjects: 18
Study 16966491 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 14985218 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (10 mg as acetate, twice daily for 5 days)
Number of subjects: 153
Study 14985218 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (10,000 microg retinol equivalents, twice daily for 4 days)
Number of subjects: 153
Study 14985218 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo for zinc and vitamin A)
Number of subjects: 153
Study 14985218 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc treatment
Number of subjects: 153
Study 14985218 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A treatment
Number of subjects: 153
Study 11380277 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric quadriceps femoris muscle exercise
Number of subjects: 24
Study 11380277 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic quadriceps femoris muscle exercise
Number of subjects: 24
Study 11380277 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic quadriceps femoris muscle exercise
Number of subjects: 24
Study 9024473 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE intervention
Number of subjects: 30
Study 9024473 — intervention group
Group type: COMPARATOR
Intervention: Comparison program
Number of subjects: 30
Study 8435972 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 95
Study 8435972 — intervention group
Group type: COMPARATOR
Intervention: Iopromide
Number of subjects: 95
Study 3535611 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol 0.5%
Number of subjects: 51
Study 3535611 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol 1%
Number of subjects: 51
Study 3535611 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 51
Study 29357921 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse sessions (attending all three sessions)
Number of subjects: 45
Study 29357921 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal group (diary return)
Number of subjects: 45
Study 29357921 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse group (diary return)
Number of subjects: 45
Study 29357921 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular pedometer use (postal group)
Number of subjects: 45
Study 25768808 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial injury prevention intervention (injury awareness programme and preventive strategies) implemented over one academic year.
Number of subjects: 343
Study 25768808 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial injury prevention intervention
Number of subjects: 343
Study 25768808 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 343
Study 23949208 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate (CH) 2.5 g
Number of subjects: 69
Study 23949208 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate (CH) 5.0 g
Number of subjects: 69
Study 23949208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 23949208 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate (CH) (both dosages)
Number of subjects: 69
Study 22789168 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI)
Number of subjects: 60
Study 22789168 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 60
Study 20564162 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (100 mg/m2 iv every 2 weeks)
Number of subjects: 73
Study 20564162 — intervention group
Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD) (20 mg/m2 iv every 3 weeks)
Number of subjects: 73
Study 20564162 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 73
Study 17098206 — intervention group
Group type: EXPERIMENTAL
Intervention: Zyoptix XP microkeratome
Number of subjects: 41
Study 17098206 — intervention group
Group type: COMPARATOR
Intervention: Intralase laser
Number of subjects: 41
Study 17098206 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 41
Study 16224085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin sodium
Number of subjects: 418
Study 16224085 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 418
Study 12192660 — intervention group
Group type: EXPERIMENTAL
Intervention: Left temporal lobe epilepsy (LTE) group
Number of subjects: 14
Study 12192660 — intervention group
Group type: COMPARATOR
Intervention: Right temporal lobe epilepsy (RTE) group
Number of subjects: 14
Study 10410403 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml of dextran 40
Number of subjects: 60
Study 10410403 — intervention group
Group type: COMPARATOR
Intervention: 1000 ml of lactated Ringer's solution
Number of subjects: 60
Study 7503169 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal acoustic stimulation to maternal abdomen
Number of subjects: 26
Study 7503169 — intervention group
Group type: COMPARATOR
Intervention: Control (fetal acoustic stimulation to nurse's arm)
Number of subjects: 26
Study 7503169 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal acoustic stimulation to maternal abdomen (crossover trial)
Number of subjects: 26
Study 7503169 — intervention group
Group type: COMPARATOR
Intervention: Placebo fetal acoustic stimulation
Number of subjects: 26
Study 7503169 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from original and crossover trials
Number of subjects: 26
Study 1688835 — intervention group
Group type: COMPARATOR
Intervention: Normal saline crystalloid solution
Number of subjects: 21
Study 1688835 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetastarch colloid solution
Number of subjects: 21
Study 7428410 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 10
Study 7428410 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (100 mg)
Number of subjects: 10
Study 7428410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30693406 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoplasty alone (group 2)
Number of subjects: 30
Study 30693406 — intervention group
Group type: EXPERIMENTAL
Intervention: K-wires augmented osteoplasty (group 3)
Number of subjects: 30
Study 30693406 — intervention group
Group type: COMPARATOR
Intervention: No consolidation (group 1)
Number of subjects: 30
Study 29653900 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame cycling
Number of subjects: 68
Study 29653900 — intervention group
Group type: COMPARATOR
Intervention: Standard bike in front of TV
Number of subjects: 68
Study 26259074 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based symptom reporting program
Number of subjects: 79
Study 26259074 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (control group)
Number of subjects: 79
Study 25079465 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic food (n=26)
Number of subjects: 52
Study 25079465 — intervention group
Group type: COMPARATOR
Intervention: Control food (n=26)
Number of subjects: 52
Study 22032759 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 25 mg/d
Number of subjects: 0
Study 22032759 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 0
Study 22032759 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d every other day
Number of subjects: 0
Study 22032759 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50/25 mg/d
Number of subjects: 0
Study 22032759 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d - placebo
Number of subjects: 0
Study 22032759 — intervention group
Group type: COMPARATOR
Intervention: No taper
Number of subjects: 0
Study 19330771 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical tool based on age of child, excess age-specific respiratory rate at baseline and at 24 hr of hospitalization; Validation sample size: 813 children.
Number of subjects: 1702
Study 19330771 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical tool based on age of child, excess age-specific respiratory rate at baseline and at 24 hr of hospitalization; Development sample size: 889 children.
Number of subjects: 1702
Study 17230059 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 67
Study 17230059 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration and type of chelation therapy
Number of subjects: 67
Study 17230059 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of beginning chelation therapy
Number of subjects: 67
Study 15494760 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational workshop
Number of subjects: 0
Study 15494760 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured prompting
Number of subjects: 0
Study 15494760 — intervention group
Group type: COMPARATOR
Intervention: Experimental group
Number of subjects: 0
Study 15494760 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12153824 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (moderate and high doses)
Number of subjects: 10
Study 12153824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10201459 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 446
Study 10201459 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg twice daily
Number of subjects: 446
Study 10201459 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg daily (maintenance)
Number of subjects: 446
Study 10201459 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily (maintenance)
Number of subjects: 446
Study 8519715 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 15 micrograms with 80 mg hyperbaric lidocaine
Number of subjects: 28
Study 8519715 — intervention group
Group type: COMPARATOR
Intervention: Normal saline with 80 mg hyperbaric lidocaine
Number of subjects: 28
Study 2167110 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolization (TAE) using iodized oil (Lipiodol) mixed with anticancer agent (ACA)
Number of subjects: 85
Study 2167110 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion (HAI) of anticancer agent (ACA)
Number of subjects: 85
Study 2167110 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chemotherapy following TAE or HAI
Number of subjects: 85
Study 206214 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision of the tumor, chemotherapy, and radiation therapy as per study protocol
Number of subjects: 606
Study 206214 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision of the tumor
Number of subjects: 606
Study 206214 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ligation of the renal vein
Number of subjects: 606
Study 206214 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete removal of tumor
Number of subjects: 606
Study 31179920 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze and Postural Stability (GPS) intervention program
Number of subjects: 50
Study 31179920 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) rehabilitation program
Number of subjects: 50
Study 28841230 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES)
Number of subjects: 599
Study 28841230 — intervention group
Group type: COMPARATOR
Intervention: Bare-Metal Stents (BMS)
Number of subjects: 599
Study 26530929 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal coaching enhanced by smartphone self-monitoring (PC)
Number of subjects: 365
Study 26530929 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 365
Study 26530929 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone intervention delivered by interactive smartphone application (CP)
Number of subjects: 365
Study 23458391 — intervention group
Group type: COMPARATOR
Intervention: 150 W xenon arc solar simulator
Number of subjects: 30
Study 23458391 — intervention group
Group type: COMPARATOR
Intervention: 300 W xenon arc solar simulator
Number of subjects: 30
Study 21200346 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with Down syndrome (DS)
Number of subjects: 18
Study 21200346 — intervention group
Group type: COMPARATOR
Intervention: Individuals without Down syndrome (non-DS)
Number of subjects: 18
Study 19666698 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with T4 (50 microg) and T3 (20 microg) for 12 weeks
Number of subjects: 59
Study 19666698 — intervention group
Group type: COMPARATOR
Intervention: T4 monotherapy for 12 weeks
Number of subjects: 59
Study 17459561 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Advisory Manikin (VAM)
Number of subjects: 50
Study 17459561 — intervention group
Group type: COMPARATOR
Intervention: Standardized Human Instruction (SHI)
Number of subjects: 50
Study 15558584 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral (cyclosporine) + prednisolone (group 1)
Number of subjects: 174
Study 15558584 — intervention group
Group type: COMPARATOR
Intervention: Neoral + placebo (group 2)
Number of subjects: 174
Study 15266173 — intervention group
Group type: EXPERIMENTAL
Intervention: 185 MBq diagnostic scan (Dscan) 4-11 days before 131I ablation (Group A)
Number of subjects: 245
Study 15266173 — intervention group
Group type: COMPARATOR
Intervention: 131I ablation directly after thyroidectomy (Group B)
Number of subjects: 245
Study 10399203 — intervention group
Group type: EXPERIMENTAL
Intervention: Mann-Whitney U-test for clustered data
Number of subjects: 0
Study 7737935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pygmalion condition (leaders believed trainees had higher potential)
Number of subjects: 0
Study 1852141 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (100 mg bid orally)
Number of subjects: 12
Study 1852141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7193603 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive 20/250 (EE/NG ratio 0.08)
Number of subjects: 98
Study 7193603 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive 30/250 (EE/NG ratio 0.12)
Number of subjects: 98
Study 7193603 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive 30/150 (EE/NG ratio 0.20)
Number of subjects: 98
Study 7193603 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-phase drug (EE/NG ratio 0.35)
Number of subjects: 98
Study 30702853 — intervention group
Group type: EXPERIMENTAL
Intervention: Real world data (RWD) studies on drug repurposing
Number of subjects: 0
Study 30702853 — intervention group
Group type: EXPERIMENTAL
Intervention: PaWei app platform
Number of subjects: 0
Study 27568321 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard surgery (JCOG9501)
Number of subjects: 678
Study 27568321 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard surgery (JCOG9502)
Number of subjects: 678
Study 27568321 — intervention group
Group type: COMPARATOR
Intervention: Experimental surgery (JCOG9501)
Number of subjects: 678
Study 27568321 — intervention group
Group type: COMPARATOR
Intervention: Experimental surgery (JCOG9502)
Number of subjects: 678
Study 27568321 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hospital gastrectomy volume (JCOG9501)
Number of subjects: 678
Study 27568321 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hospital gastrectomy volume (JCOG9502)
Number of subjects: 678
Study 26378926 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with Ecologic® Panda (B. bifidum W23, B. lactis W52, Lc. Lactis W58)
Number of subjects: 99
Study 26378926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 26378926 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic children
Number of subjects: 99
Study 26378926 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (probiotic and placebo)
Number of subjects: 99
Study 23333777 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor plus G-CSF
Number of subjects: 0
Study 23333777 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus G-CSF
Number of subjects: 0
Study 21392395 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) within 24 hours of onset
Number of subjects: 208
Study 21392395 — intervention group
Group type: COMPARATOR
Intervention: Oral diet and EN if necessary after 72 hours after hospital admission
Number of subjects: 208
Study 19145396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate (150 mg, once-monthly)
Number of subjects: 67
Study 19145396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 17640547 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional myocardial delivery of autologous cells
Number of subjects: 0
Study 17640547 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 16509251 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 412
Study 16509251 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-tuberculosis and leprosy conditions)
Number of subjects: 412
Study 11490418 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxicyclin 200 mg/day with nistatine for three weeks with 3‐week interval between the courses and bifidum‐bacterin administration between the courses and after the treatment
Number of subjects: 65
Study 11490418 — intervention group
Group type: EXPERIMENTAL
Intervention: Biseptol 1920 mg for 3 weeks then 960 mg 10 days a month
Number of subjects: 65
Study 11490418 — intervention group
Group type: COMPARATOR
Intervention: No antibacterial drugs
Number of subjects: 65
Study 9990420 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% solution
Number of subjects: 297
Study 9990420 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.025% gel
Number of subjects: 297
Study 9990420 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% solution and Tretinoin 0.025% gel
Number of subjects: 297
Study 8092895 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 393
Study 8092895 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis (rt-PA or UK)
Number of subjects: 393
Study 8092895 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 393
Study 29529387 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity stretching (30%-40% maximum perceived stretch)
Number of subjects: 30
Study 29529387 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity stretching (70%-80% maximum perceived stretch)
Number of subjects: 30
Study 29529387 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 30
Study 26893095 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel coated balloon (PCB) angioplasty
Number of subjects: 110
Study 26893095 — intervention group
Group type: COMPARATOR
Intervention: Plain old balloon angioplasty (POBA)
Number of subjects: 110
Study 24533510 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed estrogen (estradiol valerate: 2 mg for 2 years)
Number of subjects: 1017
Study 24533510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1017
Study 24533510 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed estrogen
Number of subjects: 1017
Study 23866906 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (30 minutes with a mixed current of 2 Hz/120 Hz at 80% of bearable intensity) at 12 standard acupuncture points, twice per week for eight weeks (total of 16 sessions)
Number of subjects: 45
Study 23866906 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture (no electrical current, but visual and auditory cues) at non‐acupuncture points
Number of subjects: 45
Study 23866906 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no electroacupuncture treatment)
Number of subjects: 45
Study 23866906 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 45
Study 23866906 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 45
Study 23866906 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 45
Study 20593240 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (selective COX-2 inhibitor)
Number of subjects: 38
Study 17953786 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile B (aroma profile during consumption of (soft) solids)
Number of subjects: 27
Study 17953786 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet strawberry aroma stimulation
Number of subjects: 27
Study 16981843 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent smokers (current smokers or those who quit less than 10 years ago)
Number of subjects: 1549
Study 16981843 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers who smoked more than 20 cigarettes per day
Number of subjects: 1549
Study 16981843 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT2 phenotypic activity (0: slow, 1: intermediate, 2: rapid)
Number of subjects: 1549
Study 16981843 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent smokers with NAT2*4/*5B diplotype
Number of subjects: 1549
Study 16981843 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent smokers with NAT2*4/*4 diplotype
Number of subjects: 1549
Study 16981843 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with NAT1*4/*10 diplotype
Number of subjects: 1549
Study 12702191 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-reduced RBCs (n = 25)
Number of subjects: 52
Study 12702191 — intervention group
Group type: COMPARATOR
Intervention: Nonfiltered blood (n = 27)
Number of subjects: 52
Study 11168669 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% gentian violet applied once a day for skin lesions (28 cases)
Number of subjects: 37